|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1998-2-27
|
|
pubmed:abstractText |
99mTc-sestamibi (99mTc-MIBI) is a substrate for the P-glycoprotein (P-gp) pump but it is not known whether it is a substrate for the multidrug resistance-associated protein (MRP) pump. Therefore, 99mTc-MIBI was evaluated in the GLC4 cell line and its doxorubicin-resistant MRP-, but not P-gp-, overexpressing GLC4/ADR sublines as well as in the S1 cell line and its MRP-transfected subline S1-MRP. 99mTc-MIBI concentration decreased in the GLC4/ADR sublines with increasing MRP overexpression and was lower in S1-MRP than in S1. 99mTc-MIBI plus vincristine increased 99mTc-MIBI concentration in GLC4 lines compared with 99mTc-MIBI alone. 99mTc-MIBI efflux raised with increasing MRP expression in the GLC4 lines. Glutathione depletion elevated 99mTc-MIBI concentration in GLC4/ADR150x. Cross resistance for 99Tc-MIBI, used to test cytotoxicity of the Tc compound, was observed in GLC4/ADR150x vs GLC4. 99Tc-MIBI induced a synergistic effect on vincristine cytotoxicity in GLC4/ADR150x. These results show that 99mTc-MIBI is involved in MRP-mediated efflux. The fact that 99mTc-MIBI efflux is influenced by MDR1 and MRP expression must be taken into account when this gamma-rays-emitting complex is tested for tumour efflux measurements.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-1309222,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-1360704,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-1455517,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-1680815,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-1967222,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-1982706,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-2444983,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-2544740,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-2545337,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-2570548,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-2894894,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-2899442,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-3028613,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-3553950,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-422420,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-7599070,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-7624105,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-7644478,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-7680954,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-7729950,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-7809167,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-7834606,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-7906729,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-7909602,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-7915193,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-7916458,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-7961706,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-8083699,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-8094997,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-8636432,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-8763341,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9472628-9815890
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
77
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
353-8
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:9472628-ATP-Binding Cassette Transporters,
pubmed-meshheading:9472628-Cell Survival,
pubmed-meshheading:9472628-Doxorubicin,
pubmed-meshheading:9472628-Drug Resistance, Multiple,
pubmed-meshheading:9472628-Glutathione,
pubmed-meshheading:9472628-Humans,
pubmed-meshheading:9472628-Multidrug Resistance-Associated Proteins,
pubmed-meshheading:9472628-P-Glycoprotein,
pubmed-meshheading:9472628-Technetium Tc 99m Sestamibi,
pubmed-meshheading:9472628-Tumor Cells, Cultured
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein.
|
|
pubmed:affiliation |
PET-Center, Department of Internal Medicine, University Hospital Groningen, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
